Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
National, multicenter, prospective, observational, non-interventional study. The objective is
to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated
with VKA with issues for stroke prevention in non valvular atrial fibrillation is associated
with an improvement of the treatment satisfaction after 3 months. The treatment satisfaction
will be measured by the Anti Clot Treatment Scale (ACTS) score.